Emanuel Kanal, MD

NSF, Renal Disease Patients, and Gadolinium-Based MR Contrast Agents: State of the Art

December 19, 2007 12:30 pm

Radiology Conference Room N2E14C

Emanuel Kanal is a professor of radiology and neuroradiology at the University of Pittsburg Medical Center, where he is also director of Magnetic Resonance Services. He received his medical degree from the University of Pittsburgh School of Medicine. He remained at Pitt for his internship, residency in diagnostic radiology, and 2 fellowships in neuroradiology.

A noted educator and lecturer, Dr. Kanal has been active in national and international efforts to establish guidelines for MR safety and efficacy. Most recently he has been influential in addressing the challenges associated with gadolinium-based contrast administration in MR imaging.

Among his publications are:

1. Levine GN, Gomes AS, Arai AE, Bluemke DA, Flamm SD, Kanal E, et al. for the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Radiology and Intervention. Safety of magnetic resonance imaging in patients with cardiovascular devices. Circulation. 2007;116:2878–2891. 
2. Broome DR, Cottrell AC, Kanal E. Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?" AJR Am J Roentgenol. 2007;189:W234–W235. 
3. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, Nephrogenic Systemic Fibrosis Update. Radiology. 2007; e-published on September 12 ahead of print.
4. Kanal E, Barkovich AJ, Bell C, and the members of the ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188:1447–1474. 
5. Zieman M, Kanal E. Copper T 380A IUD and magnetic resonance imaging. Contraception. 2007;75:93–95. 
6. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647–649. 
7. Mendez O, Kanal E, Abu-Elmagd KM, McFadden K, Thomas S, Bond G, Zivković SA. Granulomatous amebic encephalitis in a multivisceral transplant recipient. Eur J Neurol. 2006;13:292–295.
8. Gimbel JR, Wilkoff BL, Kanal E, Rozner MA. Safe, sensible, sagacious: responsible scanning of pacemaker patients. Eur Heart J. 2005;26:1683–1684. 
9. Gimbel JR, Kanal E, Schwartz KM, Wilkoff BL. Outcome of magnetic resonance imaging (MRI) in selected patients with implantable cardioverter defibrillators (ICDs). Pacing Clin Electrophysiol. 2005;28:270–273.
10. Towbin AJ, Kanal E. A review of two cases of fenestrated internal jugular veins as seen by CT angiography. AJNR Am J Neuroradiol. 2004;25:1433–1434.
11. Wolfe D, Niranjan A, Trichel A, Wiley C, Ozuer A, Kanal E, et al. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther. 2004;11:1675–1684.
12. Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology White Paper on MR Safety: 2004 update and revisions. AJR Am J Roentgenol. 2004;182:1111–1114. 
13. Gimbel JR, Kanal E. Can patients with implantable pacemakers safely undergo magnetic resonance imaging? J Am Coll Cardiol. 2004;43:1325–1327. 
14. Kanal E. Clinical utility of the American College of Radiology MR Safe Practice Guidelines. J Magn Reson Imaging. 2004;19:2–5. 

___________________________________________________________________

About Diagnostic Radiology Grand Rounds and CME Credit

Targeted audience: health care providers

Learning objectives: After the lecture, the attendee should be able to:

(1) List the major presenting symptoms and findings in patients with NSF;

(2) Describe the major theories about the association between NSF and administration of GBMCAs to renal disease patients;

(3) Compare similarities and differences of recommended practices from various organizations, such as the FDA, European Medicines Agency, and ACR;

(4) Compare similarities and differences among various available GBMCAs and the incidence of reports of development of NSF in renal disease patients; and

(5) List recommended practices to decrease the incidence of NSF.

Sponsored by the University of Maryland School of Medicine

Accreditation & Credit Designation Statements: The University of Maryland School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Maryland School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.